Purchase this article with an account.
Kui Dong Kang, Kyung-A Kim, Sang Hoon Jung, Su Ah Kim; The anti-angiogenic effect of tectorigenin in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):202.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Tectorigenin is an isoflavone derived from the rhizome of Belamacanda chinensis. In this study, oxygen-induced retinopathy was used to characterize the anti-angiogenic properties of tectorigenin in mice.
ICR neonatal mice were exposed to 75% oxygen from postnatal day (P)7 until P12 and returned to room air (21% oxygen) for five days (P12 to P17). Mice were subjected to daily intraperitoneal injection of tectorigenin (1 mg/kg, 10 mg/kg) and vehicle from P12 to P17. Retro-orbital injection of FITC-dextran was performed and retinal flat mounts were viewed by fluorescence microscopy. Central avascular area was quantified from the digital images in a masked fashion using image analysis software (NIH ImageJ). Neovascular tufts were quantified by using SWIFT_NV and neovascular lumens were quantified from histologic section in a masked fashion. Immunohistochemistry and Western blot analysis were also performed to demonstrate the anti-angiogenic activity of this compound in vivo.
In the retina of tectorigenin injected mouse (10mg/kg), the central non-perfusion area was significantly decreased compared to the vehicle injected group (1.76±0.5 mm2 vs 2.85±0.6 mm2, P<0.05). In vehicle-injected group, 33.45 ± 5.51% of the total retinal area was avascular, whereas the retinas of pups treated with high-dose (10 mg/kg) tectorigenin showed avascular retinal areas of 21.25 ±4.34% (P<0.05). High dose of tectorigenin also significantly reduced the number of vascular lumens in the histologic section. Tectorigenin (10 mg/kg) significantly reduced the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2), MMP-9, and angiotensin II compared to the vehicle injected group. Tectorigenin did not affect CD31 abundance at any tested dose.
Our results show that tectorigenin possesses powerful anti-angiogenic properties and can attenuates new vessel formation in the retina after systemic administration. These results implies that this compound can be considered as a candidate substance for therapeutic inhibition of retinal angiogenesis.
This PDF is available to Subscribers Only